First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation

被引：7
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 03期
关键词：
Non-small cell lung cancer; KRAS mutation; guanosine triphosphate; guanosine diphosphate; adagrasib; sotorasib; RESISTANCE; RAS;
D O I：
10.2174/0929867330666230330122000
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS(G12C). It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS(G12C )mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
引用
收藏
页码：266 / 272
页数：7
相关论文
共 50 条
  • [31] Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
    Park, C.
    Cho, H.
    Choi, Y. D.
    Oh, I.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S492 - S492
  • [32] Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
    Maristella Bungaro
    Silvia Novello
    Francesco Passiglia
    Current Treatment Options in Oncology, 2022, 23 : 1699 - 1720
  • [33] Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
    Bungaro, Maristella
    Novello, Silvia
    Passiglia, Francesco
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1699 - 1720
  • [34] Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
    Cui, Wanyuan
    Franchini, Fanny
    Alexander, Marliese
    Officer, Ann
    Wong, Hui-Li
    IJzerman, Maarten
    Desai, Jayesh
    Solomon, Benjamin J.
    LUNG CANCER, 2020, 146 : 310 - 317
  • [35] The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review
    Spagnuolo, Alessia
    Maione, Paolo
    Gridelli, Cesare
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 1199 - 1216
  • [36] Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation
    Takamori, Shinkichi
    Toyokawa, Gouji
    Shimokawa, Mototsugu
    Kinoshita, Fumihiko
    Kozuma, Yuka
    Matsubara, Taichi
    Haratake, Naoki
    Akamine, Takaki
    Mukae, Nobutaka
    Hirai, Fumihiko
    Tagawa, Tetsuzo
    Oda, Yoshinao
    Iwaki, Toru
    Iihara, Koji
    Honda, Hiroshi
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (06) : 3731 - 3734
  • [37] Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
    Tone, Mari
    Inomata, Minoru
    Awano, Nobuyasu
    Kuse, Naoyuki
    Jo, Tatsunori
    Yoshimura, Hanako
    Minami, Jonsu
    Takada, Kohei
    Miyamoto, Shingo
    Izumo, Takehiro
    ANTICANCER RESEARCH, 2020, 40 (04) : 2239 - 2246
  • [38] Nintedanib in non-small cell lung cancer: from preclinical to approval
    Caglevic, Christian
    Grassi, Massimiliano
    Raez, Luis
    Listi, Angela
    Giallombardo, Marco
    Bustamante, Eva
    Gil-Bazo, Ignacio
    Rolfo, Christian
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 164 - 172
  • [39] Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
    Ni, Jun
    Zhang, Li
    ONCOTARGETS AND THERAPY, 2021, 14 : 4087 - 4098
  • [40] Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
    Wu, Markus Y.
    Zhang, Eric W.
    Strickland, Matthew R.
    Mendoza, Dexter P.
    Lipkin, Lev
    Lennerz, Jochen K.
    Gainor, Justin F.
    Heist, Rebecca S.
    Digumarthy, Subba R.
    CANCERS, 2021, 13 (14)
12345